Please read Dr. Gaur’s article in the Pediatric Pulmonology titled, “E-cigarette or vaping product use associated lung injury (EVALI) in the time of COVID-19: A clinical dilemma.“
Vaping is the process in which liquid substances such as nicotine or tetrahydrocannabinol (THC) are heated in a device and the aerosolized particles are inhaled. Several devices are available in the market with the most common being e-cigarettes and vaping pens. The substances used in vaping devices often contain additives to aid in aerosolization and flavoring to increase marketability to adolescents. Multiple substances have been found in patient vaping devices such as vitamin E acetate, medium chain triglyceride (MCT) oil, mineral oil, silicates, solvent chemicals, and hydrocarbons, which when heated are postulated to cause increased lung injury. One study reports that in majority of cases, combined nicotine and cannabinoid containing products are used for vaping. One speculation is that counterfeit products in vaping market are also contributing to E-cigarette or vaping product use (EVALI). To read the full article.
E-cigarette or vaping product use associated lung injury (EVALI) in the time of COVID-19: A clinical dilemma. Helfgott D, Capozzoli G, Madray J, Baig A, Uppaluri L, Gaur S, Simon M, Amorosa J, Ramagopal M. Pediatr Pulmonol. 2021 Dec 29. PMID: 34964550 DOI: 1002/ppul.25804 Online ahead of print.